In addition, there was no benefit with durvalumab consolidation (PACIFIC) in unresectable stage III NSCLC or with atezolizumab maintenance in high-risk, resected, early stage disease (IMpower010) in the cohorts of patients with EGFR or ALK genetic alterations.13 The gene discussed is ALK; the disease is non-small cell lung carcinoma.